P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY

• A. Yacoub,
• U. Borate,
• R. Rampal,
• H. Ali,
• E. Wang,
• A. Gerds,
• G. Hobbs,
• M. Kremyanskaya,
• E. Winton,
• C. O’Connell,
• S. Goel,
• S. Oh,
• G. Schiller,
• A. Assad,
• S. Erickson-Viitanen,
• F. Zhou,
• N. Daver

Affiliations

A. Yacoub

1 University of Kansas Cancer Center, Westwood

U. Borate

2 Oregon Health & Science University, Portland

R. Rampal

3 Memorial Sloan Kettering Cancer Center, New York

H. Ali

4 City of Hope National Medical Center, Duarte

E. Wang

5 Roswell Park Comprehensive Cancer Center, Buffalo

A. Gerds

6 Cleveland Clinic, Cleveland

G. Hobbs

7 Massachusetts General Hospital, Boston

M. Kremyanskaya

8 Icahn School of Medicine at Mount Sinai, New York

E. Winton

9 Emory University, Atlanta

C. O’Connell

10 University of Southern California, Los Angeles

S. Goel

11 Montefiore Medical Center, Bronx

S. Oh

12 Washington University School of Medicine, St. Louis

G. Schiller

13 David Geffen School of Medicine, University of California Los Angeles, Los Angeles

A. Assad

14 Incyte Corporation, Wilmington

S. Erickson-Viitanen

14 Incyte Corporation, Wilmington

F. Zhou

14 Incyte Corporation, Wilmington

N. Daver

15 University of Texas MD Anderson Cancer Center, Houston, United States of America